Navigation Links
European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
Date:2/6/2013

NVAF). It is also being developed for the potential treatment and prevention of recurrence of VTE in patients with DVT and/or PE.[4],[5]

About PREFER in VTE

The PREFER in VTE registry enrolled the first patient in January, 2013. The registry is a multi-centre, prospective observational disease registry, with a one-year follow up. The patient sample will represent patients with acute initial or recurrent VTE (PE and/or DVT) with no exclusion criteria. Baseline visits will be conducted by investigators and standardised patient telephone follow-up interviews will be performed in regular intervals up to 12 months.

About PREFER in AF

The PREFER in AF registry is a multi-centre, prospective observational disease registry, with a one-year follow up. The patient sample will represent all AF patient groups with no exclusion criteria and irrespective of whether they receive antithrombotic therapy or not.

About VTE
VTE is the term for the generation of a blood clot within a vein, or the subsequent breaking off of that clot into a pulmonary (lung) artery.[6] DVT and PE are the two sub-types of VTE.[7] DVT is caused by a blood clot anywhere in the deep veins of the legs, pelvis or arms.[8] PE is caused by a clot that detaches from the vein and travels to the lungs,[8] lodging in the pulmonary arteries causing a potentially fatal condition.[8],[9] PE is often accompanied by DVT and a DVT can develop into a PE suddenly.[9] It is estimated that VTE is the cause of approximately 12% of annual deaths across Europe.[1]

As demonstrated by data from six major European countries, VTE affects more than 750,000 people annually.[1] Traditional therapies are often inconvenient and cumbersome, due to food and drug interactions, as well as the need for strict international normalized ratio (INR) monitoring.  

Abo
'/>"/>

SOURCE Daiichi Sankyo Europe GmbH
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
2. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
5. Mylan Launches Generic Lipitor® in Five European Countries
6. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
7. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
10. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapies for the treatment ... Timothy E. Morris , chief financial officer  will be ... events are as follows: Mizuho Third Annual ...  The Omni Berkshire Place, New York ...
(Date:5/1/2015)... -- Shares of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI ) ... results of the Phase 3 Rocket 1 trail of ... to meet its end points, compelling data from the ... studies. An analyst report on AERI that ... analyst summary, valuation, and recommendation can be viewed by ...
(Date:4/30/2015)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the fourth quarter and fiscal year ... fiscal 2015 overview: , Revenues from continuing operations ... over last year,s comparable quarter, and $202.6 million for ... of $0.50 for the fourth quarter, up 194% over ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 2Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 3Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 4Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 5Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 6Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 7Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 8Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 9Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 10Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 11Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 12Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 13Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 14Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 15Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 16Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 17Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 18Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 19Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 20Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 21Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 22Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 23Abaxis Reports Financial Performance for the Fourth Quarter and Fiscal 2015 and Declares a 10% Increase in Quarterly Cash Dividend 24
... announced today,that it has begun enrollment of the ... eluting coronary stent clinical trial. Atrium,s,European FIM clinical ... stent system., This First-in-Man trial is a ... CINATRA(TM) voclosporin coated,coronary stent system, which will be ...
... Results for SB-509 in Development for ... 8 Sangamo BioSciences,Inc. (Nasdaq: SGMO ) ... data from its ZFP Therapeutic(TM) program at the ... As,disclosed in an oral presentation entitled, "Evidence of ...
Cached Medicine Technology:Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent 2Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 2Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 3Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 4Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 5Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 6Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 7Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 8Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting 9
(Date:5/3/2015)... It is not too late to register to take part ... Lissa Anne Been in Arnold, Missouri on May 9, 2015. ... honor her loving memory. It has benefited the renowned Brain Aneurysm ... 37, Lissa suffered a brain aneurysm . After two operations ... event is designed to serve as a remembrance of her and ...
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
(Date:5/2/2015)... ProText Kinetic 2 is a set of typography ... X. ProText Kinetic 2 features 40 animation presets ... X . Easily create interactive text videos without having ... Kinetic 2. , Using ProText Kinetic is as easy as ... presets in the FCPX timeline. Playback the default animation ...
(Date:5/2/2015)... Peachtree Audio ” was featured on NewsWatch as part ... and coolest technology products available to consumers. Scott Steinberg, ... the review and shared with viewers how this is ... important part of people’s lives – and as such, ... Peachtree Audio does just that with high-end audio equipment ...
(Date:5/2/2015)... 02, 2015 As a nonsurgical ... of the face, neck and décolleté, radiofrequency energy ... real potential for the success of vulvovaginal rejuvenation. ... Clinical Advisory Council, ThermiGyn’s Women’s Health Clinical Advisory ... concluded that ThermiGyn’s temperature controlled radio frequency, specifically ...
Breaking Medicine News(10 mins):Health News:Renowned Brain Aneurysm Foundation to Benefit from Arnold, Missouri’s 3rd Annual Brain Aneurysm Walk in Memory of Lissa Anne Been 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 2Health News:Study Demonstrates Efficacy of Temperature Controlled Radiofrequency for Vulvovaginal Laxity 3
... Scottish Health officials have warned that their National dish ‘Haggis’ ... increase the obesity in their people. Scottish people are now ... officials has said //that children’s should not have Haggis not ... a Traditional food which is prepared from lung, liver and ...
... treatment for severe acute respiratory syndrome (SARS) may not be ... to latest reports. It may just serve to alleviate their ... researchers of the present study analyzed 12 different clinical trials ... with both allopathic and Chinese medicines were included for the ...
... therapy should be considered by women who suffer from stage ... according to a research which says// that this can prolong ... to be the most common. As many as 40,000 women ... US alone, according to the data of the American Cancer ...
... Post doc Daniel Stetson have reported in the Journal Immunity ... to viral DNA infection. // ,Viruses are classified ... and researchers have found that immune response which acts in ... for DNA and RNA viruses. ,Immune response against ...
... patients at Swansea psychiatric hospital, it is said that patients are ... of kitchens at Cefn Coed Hospital//. ,The claims made say ... the kitchens at Cefn Coed Hospital. , ,The closure of ... to what it called a "cook chill" system. , ,The ...
... A new study conducted by researchers at the ... says that elderly individuals who take the blood ... osteoporosis-linked bone fractures. ,"We did a ... patients hospitalized with atrial fibrillation, and we identified ...
Cached Medicine News:Health News:Blood Thinners Linked To Osteoporotic Fractures 2
Shandon Laser MicroWriter is a laser labeling system developed specifically for anatomical pathology....
Eberbach's 2800 Series Micro Slide Cabinets provide safe, short-term and long-term, storage of prepared slides which can easily be indexed for retrieval. Cabinets are available in (2) two styles, a U...
Compact storage cabinets for 35 mm slides....
Fisherbrand* Micro Slide Cabinet is made of heavy gauge, reinforced steel....
Medicine Products: